News Image

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Provided By GlobeNewswire

Last update: Feb 4, 2025

– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 –

NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the publication of results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1 (Arg1), in the Journal for ImmunoTherapy of Cancer.

Read more at globenewswire.com

IO BIOTECH INC

NASDAQ:IOBT (6/13/2025, 8:11:12 PM)

After market: 1.35 0 (0%)

1.35

-0.15 (-10%)



Find more stocks in the Stock Screener

Follow ChartMill for more